{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:58Z","timestamp":1791223558711,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1136\/ard-2022-222748","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T13:20:13Z","timestamp":1674480013000},"page":"639-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02446912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446899","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01438489","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01438489","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446899","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-1585","authenticated-orcid":false,"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-4445","authenticated-orcid":false,"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222748_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrrheum.2014.118","article-title":"The need to define treatment goals for systemic lupus erythematosus","volume":"10","author":"Franklyn","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international Task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib4","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international Task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222748_bib5","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","volume":"1","author":"Golder","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2022-222748_bib6","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2665-9913(19)30049-9","article-title":"Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials","volume":"1","author":"Parodis","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib8","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222748_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222748_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222748_bib13","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","article-title":"Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2B address II study","volume":"59","author":"Morand","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222748_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/annrheumdis-2017-212504","article-title":"Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab","volume":"77","author":"Morand","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222748_bib17","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib18","author":"AstraZeneca"},{"key":"10.1136\/ard-2022-222748_bib19","author":"EMA"},{"key":"10.1136\/ard-2022-222748_bib20","author":"FDA"},{"key":"10.1136\/ard-2022-222748_bib21","author":"Health Canada"},{"key":"10.1136\/ard-2022-222748_bib22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222748_bib23","first-page":"1459","article-title":"Attainment of the lupus low disease activity state in response to anifrolumab in 2 phase 3 trials","volume":"73","author":"Morand","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222748_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/14737167.5.3.317","article-title":"Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies","volume":"5","author":"Strand","year":"2005","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1136\/ard-2022-222748_bib26","article-title":"Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets [abstract]","volume":"74","author":"Van Vollenhoven","year":"2022","journal-title":"Arthritis Rheumatology"},{"key":"10.1136\/ard-2022-222748_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrrheum.2016.174","article-title":"Connective tissue diseases: remission in SLE - are we there yet?","volume":"12","author":"Morand","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib28","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international Task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib30","doi-asserted-by":"crossref","first-page":"e000625","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222748_bib31","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222748_bib32","doi-asserted-by":"crossref","first-page":"keab777","DOI":"10.1093\/rheumatology\/keab777","article-title":"Measurement of specific organ domains in lupus randomized controlled trials: a scoping review","volume":"61","author":"Connelly","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222748_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, Fifty-Two-Week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222748_bib34","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222748_bib35","doi-asserted-by":"crossref","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222748_bib36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"}],"updated-by":[{"DOI":"10.1136\/ard-2022-222748corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:41Z","timestamp":1739504141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724084632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003496724084632"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222748","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}